These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 27545626)

  • 21. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ; González EA
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
    Noto L
    J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone cell biology and pediatric renal osteodystrophy.
    Haffner D; Fischer DC
    Minerva Pediatr; 2010 Jun; 62(3):273-84. PubMed ID: 20467380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of phosphate binders in chronic kidney disease.
    Ketteler M; Biggar PH
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
    Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
    Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular calcification in end-stage renal disease patients.
    Nitta K; Ogawa T
    Contrib Nephrol; 2015; 185():156-67. PubMed ID: 26023025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on the treatment of chronic kidney disease-mineral and bone disorder.
    Bover J; Farré N; Andrés E; Canal C; Olaya MT; Alonso M; Quílez B; Ballarín J
    J Ren Care; 2009 Mar; 35 Suppl 1():19-27. PubMed ID: 19222727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphate binders in chronic kidney disease. When should we start, what should we prescribe?
    Malindretos P
    Expert Opin Pharmacother; 2012 Nov; 13(16):2255-6. PubMed ID: 23046412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of mineral and bone disorders in chronic kidney disease (CKD-MBD) in adults.
    Bellorin-Font E; Ambrosoni P; Carlini RG; Carvalho AB; Correa-Rotter R; Cueto-Manzano A; Jara A; Jorgetti V; Negri AL; Olaizola I; Salusky I; Slatopolsky E; Weisinger JR; ;
    Nefrologia; 2013; 33 Suppl 1():1-28. PubMed ID: 23629678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Iron-based Phosphate Binders for ESRD Patients].
    Cozzolino M; Mangano M; Magagnoli L; Di Lullo L; Galassi A; Brancaccio D; Bellasi A
    G Ital Nefrol; 2016; 33(4):. PubMed ID: 27545638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction].
    Negi S; Yamanaka S; Koreeda D; Yashiro M; Shigematsu T
    Clin Calcium; 2012 Oct; 22(10):1557-66. PubMed ID: 23023637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.
    Moe SM; Radcliffe JS; White KE; Gattone VH; Seifert MF; Chen X; Aldridge B; Chen NX
    J Bone Miner Res; 2011 Nov; 26(11):2672-81. PubMed ID: 21826734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The expanding concept of CKD-MBD].
    Komaba H
    Clin Calcium; 2016 Sep; 26(9):1253-60. PubMed ID: 27561339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Bone disease in chronic renal failure and its modern therapy].
    Dusilová Sulková S
    Vnitr Lek; 2011; 57(7-8):620-5. PubMed ID: 21877595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Chronic kidney disease-mineral and bone disorder (CKD-MBD)].
    Hamada Y; Fukagawa M
    Nihon Rinsho; 2006 Sep; 64(9):1703-6. PubMed ID: 16972683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regression of vascular calcification in a parathyroidectomized patient on dialysis with untreated hypocalcemia over 12-year follow-up
.
    Molina P; Górriz JL; Beltrán S; Vizcaino B; Pallardo LM
    Clin Nephrol; 2016 Dec; 86 (2016)(12):333-339. PubMed ID: 27719736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of treatment of renal osteodystrophy on bone histology.
    Malluche HH; Mawad H; Monier-Faugere MC
    Clin J Am Soc Nephrol; 2008 Nov; 3 Suppl 3(Suppl 3):S157-63. PubMed ID: 18988701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?
    Negri AL
    J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Challenges in the therapy of secondary hyperparathyroidism.
    Wood C; González EA; Martin KJ
    Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.